Laura Joszt, MA

Patients with acute myeloid leukemia (AML) who relapse after first-line treatment face a substantial health care resource utilization (HCRU) and cost burden, according to a poster presented at Virtual ISPOR 2021.

With a variety of treatments available for chronic lymphocytic leukemia (CLL), a disease that is extremely heterogeneous, clinicians are faced with a challenging task to choose the right treatment for a patient.

Patients with sickle cell disease face substantial health care utilization and impaired health-related quality of life (HRQOL).

Technological innovation is helping to reinvent the traditional health economics and outcomes research (HEOR) field as traditional and new players partner to leverage data sources.

Stakeholders identify the value elements of comprehensive genomic profiling (CGP) they find most important, as well as options for innovative contracts.

As the cost of therapies increases, US health plans are utilizing tools like step therapy, to ensure patients try cheaper alternatives first, and value assessment frameworks, to assist with the decision-making process.

With more than 3000 gene therapies in development, payers will have to grapple with the challenges of paying for these innovative but expensive therapies.

During a panel at Virtual ISPOR 2021, speakers presented global perspectives of COVID-19 vaccine rollout and efforts to target vaccine-hesitant communities.

Two posters presented at Virtual ISPOR 2021 analyzed the health care resource utilization and cost of patients with chronic obstructive pulmonary disease (COPD) with pneumonia, as well as the cost savings of treating patients with frequent or severe COPD exacerbations with a fixed-dose triple therapy.

The COVID-19 pandemic brought together the world and taught health systems how to be resilient and adapt to both predictable and unpredictable changes, said the panelists during the plenary on day 1 of Virtual ISPOR 2021.

The 4-day annual meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research—will cover a wide range of topics. Here are 5 themes to keep an eye out for.

Asthma exacerbations among Black/African American and Hispanic/Latinx adults with moderate-to-severe asthma decreased by approximately 40% during the COVID-19 pandemic, particularly among individuals who worked outside the home and those without type 2 inflammation.

BK virus–specific T cells from healthy donors were an effective and safe off-the-shelf treatment for patients with leukemia or lymphoma who developed a painful and common complication after allogeneic hematopoietic stem cell transplantation.

As people socially distanced during the COVID-19 pandemic, the problems of loneliness and social isolation were exacerbated.

Patients with pulmonary arterial hypertension (PAH) who have comorbidities or advanced age who are treated with a monotherapy have comparable outcomes to patients on combination therapies.

Posters from the Academy of Managed Care Pharmacy annual meeting evaluated real-world evidence on adherence to biosimilars and barriers to biosimilar adoption.

A text message–based intervention successfully increased step counts for patients with pulmonary arterial hypertension (PAH).

Skin cancer is one of the most common diseases dermatologists deal with on a daily basis, and as global rates increase, it is clear that climate change is a contributory factor, said Eva R. Parker, MD, FAAD, assistant professor of dermatology, Vanderbilt University Medical Center, during her session at the American Academy of Dermatology Virtual Meeting Experience.

Unsurprisingly, the use of telemedicine grew exponentially during the COVID-19 pandemic, but those changes are not here to stay without major policy changes, according to speakers at the American Academy of Dermatology Virtual Meeting Experience 2021.

Posters presented at the American Academy of Dermatology Virtual Meeting Experience show ruxolitinib cream was effective at treating atopic dermatitis (AD) regardless of previous treatments and in patients with more severe disease.

Until now, treatments for atopic dermatitis have had safety concerns, but a new understanding of the disease has led to novel and exciting agents being developed, according to Emma Guttman, MD, PhD, of Mount Sinai.

Posters presented at the American Academy of Dermatology Virtual Meeting Experience highlighted that ruxolitinib cream is effective in patients with more severe atopic dermatitis, and even showed clinically relevant improvements in patients who only had a partial response.

While the introduction of sodium glucose co-transporter 2 (SGLT2) inhibitors has benefitted patients with type 2 diabetes and impacted guidelines globally, these expensive therapies have managed care implications, explained Richard E. Pratley, MD, of AdventHealth Diabetes Institute and Johns Hopkins University School of Medicine.

Patients with atopic dermatitis (AD) who received ruxolitinib cream experienced a rapid, clinically meaningful, and sustained improvement in their itch.

Mitigating the burden of HIV in the United States means taking a more comprehensive approach to diagnosis, testing, and treatment of the disease, said a speaker at the National Association of Managed Care Physicians Virtual Spring Managed Care Forum.

Metastatic breast cancer has a poor prognosis, but emerging targeted therapies are providing some progress in the treatment of the disease, explained Filipa Lynce, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School.

While bosentan and sildenafil is a common combination therapy in patients with pulmonary arterial hypertension (PAH), patients may need to transition to alternative therapy because of the potential for drug-drug interactions with this combination.

During her opening plenary at the NAACOS Spring 2021 Conference, Liz Fowler, PhD, JD, deputy administrator and director of the Center of Medicare and Medicaid Innovation, highlighted how the center is taking a pause to reassess its models and what is coming next.

An educational nursing program can positively impact medication compliance in patients receiving oral pulmonary arterial hypertension (PAH) therapies.

The upcoming 2021 virtual meeting of the American Academy of Dermatology (AAD) will offer more than 75 sessions. Some of the topics to keep an eye out for include treating minority populations, the impact of COVID-19, and patients with cancer.